SEARCH

SEARCH BY CITATION

References

  • 1
    Crawley FP. The Limits of the Declaration of Helsinki. Address to Scientific Session, World Medical Association General Assembly, September 2003, Helsinki.
  • 2
    Macklin R. Future challenges for the Declaration of Helsinki: Maintaining Credibility in the Face of Ethical Controversies. Address to Scientific Session, World Medical Association General Assembly, September 2003, Helsinki.
  • 3
    The World Medical Association Ethics Unit. Declaration of Helsinki. Accessed 5 November 2003, http://www.wma.net/e/ethicsunit
  • 4
    Vanhoozer KJ. Is There a Meaning in this Text? Grand Rapids, MI: Zondervan, 1998; 1729.
  • 5
    Madison GB. Hermeneutics. Gadamer and Ricoeur. In Pimlico History of Western Philosophy, ed. PopkinRH. London: Pimlico, 1999; 70512.
  • 6
    Human Experimentation: code of ethics of the World Medical Association. Br Med J 1964; 2: 177.
  • 7
    Fluss S. How the Declaration of Helsinki developed. Good Clin Prac J 1999; 6: 1821.
  • 8
    World Medical Association. Declaration of Helsinki. 1964.
  • 9
    Flanigan A. Who wrote the Declaration of Helsinki? JAMA 1997; 277: 926.
  • 10
    World Medical Association. Declaration of Helsinki, 2nd (Venice) amendment. 1983.
  • 11
    World Medical Association. Declaration of Helsinki, 3rd (Hong Kong) amendment. 1989.
  • 12
    World Medical Association. Declaration of Helsinki, 4th (Somerset West) amendment. 1996.
  • 13
    Temple R. Impact of the Declaration of Helsinki on Medical Research from a Regulatory Perspective. Address to the Scientific Session, World Medical Association General Assembly, September 2003, Helsinki.
  • 14
    Nicholson R. Editorial. Bull Med Ethics 2000; 162: 1.
  • 15
    Human D, Fluss S. The World Medical Association's Declaration of Helsinki: Historical and Contemporary Perspectives. http://www.wma.net/e/ethicsunit/pdf/draft_historical_contemporary_perspectives.pdf (accessed November 5, 2003).
  • 16
    World Medical Association. Chapter 4. The Declaration of Helsinki. http://www.wma.net/e/ethicsunit/pdf/chapter_4_decl_of_helsinki.pdf (Accessed November 5 2003).
  • 17
    Levine RJ. Some recent developments in the International Guidelines on the Ethics of Research Involving Human Subjects. Ann NY Acad Sci 2000; 918: 1707.
  • 18
    Emanuel EJ, Miller FG. Placebo-controlled trials – a middle ground. New Engl J Med 2001; 345: 9159.
  • 19
    Rothman KJ, Michel KB. The continuing unethical use of placebo-controlled trials. New Engl J Med 1994; 331: 3948.
  • 20
    Weijer C, Dickens B, Meslin E. Bioethics for clinicians: 10. Research ethics. Can Med Assoc J 1997; 156: 11537.
  • 21
    Rothman KJ. Placebo mania. Br Med J 1996; 313: 34.
  • 22
    Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med 1999; 341: 5314.
  • 23
    Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 2000; 133: 45664.
  • 24
    Neda N. Impact of the Declaration of Helsinki on Medical Research in the Developing World. Address to Scientific Meeting, World Medical Association Annual Assembly, September 2003, Helsinki.
  • 25
    Nuffield Council on Bioethics. The Ethics of Research Related to Healthcare in Developing Countries. London: Nuffield Council, 2002; 87.
  • 26
    Bienenfeld L, Frishman W, Glasser SP. The placebo effect in cardiovascular disease. Am Heart J 1996; 132: 120721.
  • 27
    Weber MA. The ethics of using placebos in hypertension clinical trials. J Hypertens 1999; 17: 58 (Editorial).
  • 28
    Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Moller HJ. Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psych Clin Neurosci 2003; 253: 228.
  • 29
    Carpenter WT, Appelbaum PS, Levine RJ. The declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry 2003; 160: 35662.
  • 30
    Delmas PD, Calvo G, Boers M et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 2002; 13: 15.
  • 31
    Brody BA, Dickey N, Ellenberg SS et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J Bone Miner Res 2003; 18: 11059.
  • 32
    Charney DS, Nemeroff CB, Lewis L et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch General Psychiatry 2002; 59: 26270.
  • 33
    Michels KB, Rothman KJ. Update on unethical use of placebo in randomised trials. Bioethics 2003; 17: 188204.
  • 34
    Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 5th edn. New York: Oxford University Press, 2001; 2267.
  • 35
    World Medical Association. WMA to Continue Discussion on Declaration of Helsinki. Press release September 14 2003.http://www.wma.net/e/press/2003_19.htm(Accessed 5 November 2003).
  • 36
    Frankish H. WMA postpones decision to amend Declaration of Helsinki. Lancet 2003; 362: 963.
  • 37
    Editorial. One standard, not two. Lancet 2003; 362: 1005.
  • 38
    Carlson R, Boyd W, Webb D. One standard, not two. Lancet 2003; 362: 1761 (letter).
  • 39
    Capron AM. Address to the WMA Council Meeting, Divonne-les-Bains, France, May 2003.
  • 40
    Riis P. Perspectives on the fifth revision of the Declaration of Helsinki. JAMA 2000; 284: 30456.
  • 41
    World Medical Association.The Law and Medical Ethics.http://www.wma.net/e/press/2003_6.htm (Accessed 5 November 2003).
  • 42
    World Medical Association. Documentation for the Preparation of Note of Clarification on Paragraph 19 of the Revised Declaration of Helsinki. http://www.wma.net/e/ethicsunit/helsinki.htm (date="2003-accessed-05">Accessed 5 November 2003).
  • 43
    Godlee F. The ethics of peer review. In Ethical Issues in Biomedical Publication, eds Hudson JonesA, McLellanF. Baltimore: Johns Hopkins University Press, 2000; 78.
  • 44
    Delamonthe T, Smith R. Open access publishing takes off. Br Med J 2004; 328: 13.
  • 45
    Idanpaan-Heikkila JE. The Declaration of Helsinki and Other International Ethical Documents Guiding Physicians in the Conduct of Medical Research. Address to the Scientific Session of the General Assembly, World Medical Association, Helsinki, 1014 September 2003.
  • 46
    Richards T. The World Medical Association: can hope triumph over experience? Br Med J 1994; 308: 2626.
  • 47
    Carlson RV, Boyd KM, Webb DJ. The Declaration of Helsinki's international guidelines for research ethics: past, present and future. Br J Clin Pharmacol 2003; 55: 4212.
  • 48
    Myllymaki K. Welcome Address to the Scientific Session of the General Assembly. World Medical Association, Helsinki, 1014 September 2003.
  • 49
    Nuffield Council on Bioethics. The Ethics of Research Related to Healthcare in Developing Countries. London: Nuffield Council, 2002; 8598.
  • 50
    Englehardt HT. The Foundations of Bioethics, 2nd edn. New York: Oxford University Press, 1996; 14.
  • 51
    Leven K-H. The invention of Hippocrates: oath, letters and Hippocratic corpus. In Ethics Codes In Medicine, eds TrohlerU, Reiter-TheilS. Aldershot: Ashgate, 1998; 323.
  • 52
    Lewis CS. Till We Have Faces: A Myth Retold. London: Fount, 1956; 31920.
  • 53
    Sass H-M. Reichsrundschreiben 1931: Pre-Nuremberg German regulations concerning new therapy and human experimentation. J Med Philos 1983; 8: 99111.
  • 54
    Weisstub DN. The ethical parameters of experimentation. In Research on Human Subjects, ed WeisstubDN. Oxford: Elsevier Science, 1998; 4.